Annex A - Discussion paper on novel formulations of supplement compounds designed to increase oral bioavailability

Abbreviations

TOX/2025/09

Last updated: 19 March 2025

ASA

Advertising Standards Authority

AUC0-n

Integrated area under the time-concentration curve following administration of a compound from 0 to n hours.

BCM-95

Curcumin formulation composed of 95% standardised curcuminoids and turmeric essential oils.

BDMC

Bisdemethoxycurcumin

BMI

Body mass index

CBD

Cannabidiol

Cmax

Highest plasma concentration achieved following administration of a compound.

COT

The Committee on Toxicity of Chemicals in Food, Consumer Products, and the Environment

DAGs

Diacylglycerols

DMC

Demethoxycurcumin

FFA

Free fatty acids

GIT

Gastrointestinal tract

GRAS

Generally recognised as safe.

HBGV

Health-based guidance value

LCFA

Long chain fatty acids

MAGs

Monoacylglycerols

MCT

Medium chain triglycerides

MTHF

Methyltetrahydrofolate

NAD+

Nicotinamide adenine dinucleotide

NIH

National Institutes of Health

NLC

Nanostructured lipid carriers

NMN

Nicotinamide mononucleotide

PDI

Polydispersity index

SE(M/N)DDS

Self-emulsifying (micro/nano) drug delivery system

SLCP

Solid lipid curcumin particles

SLN

Solid lipid nanoparticles

THC

Tetrahydrocurcumin (c.f. the cannabinoid tetrahydrocannabinol ‘THC’, is not discussed in this paper)

Tmax

Timepoint following administration of a compound at which highest plasma concentration is achieved.